A retrospective cohort study comparing an increased risk of non-infectious uveitis or myasthenia gravis to patients on non-checkpoint inhibitor chemotherapy
Latest Information Update: 26 Apr 2022
At a glance
- Drugs Antineoplastics (Primary) ; Atezolizumab (Primary) ; Avelumab (Primary) ; Cemiplimab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 26 Apr 2022 New trial record